Tuesday, April 06, 2021 2:37:26 PM
https://www.marketwatch.com/press-release/oral-mucositis-drugs-market-size-2021-2026-industry-trends-size-segments-competitors-classification-growth-up-and-down-stream-industry-analysis-and-forecast-2021-02-15
https://drug-dev.com/gastrointestinal-drugs-market-to-hit-48-4-billion/
https://www.businesswire.com/news/home/20210210005504/en/Global-Anti-Viral-Drug-Therapy-Market-2020-to-2030---Opportunities-and-Strategies-with-COVID-19-Implications-and-Growth---ResearchAndMarkets.com
https://www.gminsights.com/pressrelease/oncology-market#:~:text=Oncology%20Market%20size%20is%20set,by%20Global%20Market%20Insights%2C%20Inc.
The world's best-selling drug, Humira, took 15 years for its sales to go from $250M in 2003 to nearly $20B in 2018. The point here is that approved-effective drugs take time to ramp-up to the billion-dollar+ sales arena.
Additonally, oral mucositis is not even, globally, a billion-dollar market and the gastrointestinal market comes with major competition from the likes of AbbVie, JNJ, Allergan & AstraZeneca. Also:
https://drug-dev.com/gastrointestinal-drugs-market-to-hit-48-4-billion/
B-COVID advantage over other B/indications is: Market Opportunity
https://www.google.com/search?q=market+opportunity+definition&rlz=1CAKDUD_enUS930&oq=market+opportunity&aqs=chrome.2.69i57j0l9.10398j0j7&sourceid=chrome&ie=UTF-8
Globally, substantial market opportunities await B-COVID in the form of bulk billion-dollar buyers around the world and the coronavirus variants will only serve to make B-COVID even more valuable.
Leo is working hard to get B-COVID up and running and, IMO, he would be unwise to expend IPIX's precious capital on further development of B-OM and B-UC/CD (gastrointestinal area). IMO, Leo should be solely focused on B-COVID and the development of B as a broad spectrum anti-viral drug therapy (AVDT).
B-COVID, judging from the sales experience of vaccines, will generate billion$ in MONTHS not YEARS and once revenues start rolling in Leo, IMO,should turn his attention back to the development of "K" for Ovarian cancer because Ovarian Carcinomas are
http://www.ipharminc.com/therapeutic-areas/
I believe the course of action I am proposing is consistent with the sales projections and market size for the above indications.
The logic here is very simple and best stated by the late bank robber Willie Sutton who, arrested and walking into FBI HQ, was asked, "Why do you rob banks?" Sutton's response:
“Because that's where the money is.”
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM